Pharmaceuticals

"Pharmaceuticals" Main

Latest Morning Briefing Stories

KFF Health News' 'What the Health?': 2023 Is a Wrap

Podcast

2023 was another busy year in health care. As the covid-19 pandemic waned, policymakers looked anew at long-standing obstacles to obtaining and paying for care in the nation’s health care system. Meanwhile, abortion has continued to be an issue in much of the nation, as states respond to the Supreme Court’s 2022 decision overturning the constitutional right to the procedure. This week, Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of Johns Hopkins University and Politico Magazine join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and wrap up the year in health. Also this week, Rovner interviews KFF Health News’ Jordan Rau about his joint KFF Health News-New York Times series “Dying Broke.”

Millions of Dollars Flow From Pharma to Patient Advocacy Groups

KFF Health News Original

Pharma money is all over the place — in universities, companies doing continuing medical education for doctors and in prominent patient advocacy organizations that are household names across America. Public Citizen, a consumer advocacy nonprofit, reports today that between 2010 and 2022, the drug industry’s main lobbying group and member companies provided at least $6 […]

Colorado Says Drug Industry Blocked Its Canada Dreams – And Biden Hasn’t Helped

KFF Health News Original

Colorado’s leaders had grand plans to import cheaper medicines from Canada, after the Trump administration issued rules in 2020 allowing states to try it. But officials in Denver say they’ve been stymied by opposition from drugmakers — as well as the Biden administration’s inaction on the policy. That’s according to a Dec. 1 report we […]

Many Autoimmune Disease Patients Struggle With Diagnosis, Costs, Inattentive Care

KFF Health News Original

Despite the prevalence of autoimmune conditions, like the thyroid disease Hashimoto’s, sometimes finding help can prove frustrating as well as expensive. There are often no definitive diagnostic tests, so patients may rack up big bills as they search for confirmation of their condition and for treatment options.